Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings
Background: Human albumin (HA) is an effective adjuvant treatment for patients with cirrhosis developing spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS) and ascites requiring large-volume paracentesis (LVP). However, cost remains a barrier to use, particularly in resource-limited...
Saved in:
Main Authors: | Irsan Hasan (Author), Ignatia Sinta Murti (Author), Putut Bayupurnama (Author), Kemal Fariz Kalista (Author), Christina Hill-Zabala (Author), Dennis Kananda (Author), Elisabet Viayna (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Application of Stem Cell Therapy for Liver Cirrhosis: Progress, Pitfalls, and Prospects
by: Prenali Dwisthi Sattwika, et al.
Published: (2022) -
Induced Rhabdomyolysis Associated With Decompensated Cirrhosis
by: William Dungan MD, et al.
Published: (2022) -
Urinary albumin-to-creatinine ratio in decompensated liver cirrhosis among elderly Egyptian patients: a single-center experience
by: Ahmed Abdelghani, et al.
Published: (2021) -
Buschke-Lowenstein tumor in a patient with decompensated cirrhosis
by: F. N. U. Shailesh, et al.
Published: (2014) -
Cryptococcemia in an HIV-negative patient with decompensated liver cirrhosis
by: Manasa Kandula, et al.
Published: (2016)